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background: Lorcaserin (lor) is a selective 5-HT2C receptor agonist indicated for chronic weight management as an adjunct to lifestyle 
modification. Valvulopathy has been associated with nonselective serotonergic agonists; however, the phase 3 trials showed no significant increase 
in valvulopathy in patients (pts) on lor (relative risk ~1.1, lor vs placebo; P=0.47). This analysis of the phase 3 studies sought to evaluate the effect 
of lor on pts with valvulopathy prior to taking lor.
methods: Serial echocardiographs were performed at baseline (BL) and every 6 months in BLOSSOM (4,008 pts without type 2 diabetes 
[T2D] and BMI 30-45 kg/m2 or 27-29.9 kg/m2 with ≥1 weight-related comorbidity) and BLOOM-DM (604 pts with T2D and BMI 27-45 kg/m2). 
Echocardiographs were performed over 1 year (W52) in 168 pts with BL valvulopathy. American Society of Echocardiography criteria were used by an 
independent core lab with 2 blinded cardiologists. The primary endpoint is change in regurgitation from BL to W52 (last observation carried forward).
results: The majority of shifts from BL to W52 were single-grade changes (Figure), with more pts demonstrating a decrease in regurgitation than an 
increase. At W52, 57.8% and 52.9% of lor and placebo pts with BL valvulopathy no longer met these criteria, using FDA criteria.
conclusions: Lor pts with preexisting valvulopathy did not show progression of valve disease up to 1 year. Most showed regression of their 
regurgitation, which was comparable to the placebo group.
 
